Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07263711

Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction

A Prospective Real-World Study of Pathology Artificial Intelligence for Predicting Molecular Alterations in Gliomas

Status
Recruiting
Phase
Study type
Observational
Enrollment
2,000 (estimated)
Sponsor
Nanfang Hospital, Southern Medical University · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical study is to learn if an artificial intelligence (AI) model can accurately predict important molecular changes in gliomas, a type of brain tumor, using digital pathology images. The main questions this study aims to answer are: How accurate is the AI model in predicting key molecular alterations compared with standard molecular testing? Can the AI model shorten the time needed for diagnosis and reduce the need for expensive molecular tests? Researchers will collect whole slide images from multiple hospitals and use the AI model to predict molecular results. The predictions will be compared with the actual test results from standard laboratory methods. Participants will: Allow the use of their pathology images and molecular test results for research. Have no additional treatments or procedures beyond standard medical care. This study will help determine whether AI-assisted tools can provide faster and lower-cost molecular diagnosis for glioma, improving patient care and supporting equal access to precision medicine.

Conditions

Timeline

Start date
2025-09-01
Primary completion
2030-09-01
Completion
2030-09-01
First posted
2025-12-04
Last updated
2025-12-04

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07263711. Inclusion in this directory is not an endorsement.